Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M W Baseler

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)|October 1, 1981
Acute-phase reactants in experimental inhalation lung diseaseM W Baseler, R Burrell
Inflammation|December 1, 1983
Purification of haptoglobin and its effects on lymphocyte and alveolar macrophage responsesM W Baseler, R Burrell
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1992
Immunological monitoring and clinical trials of biological response modifiersM W Baseler, W J Urba
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1990
Immunological monitoring and clinical trials of biological response modifiersW J Urba, M W Baseler
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1991
Immunological monitoring and clinical trials of biological response modifiersM W Baseler, W J Urba
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1988
Immunological monitoring and clinical trials of biological response modifiersW J Urba, M W Baseler
Infection and Immunity|April 1, 1983
Differential toxicity of inhaled gram-negative bacteriaM W Baseler, B Fogelmark, R Burrell
Cancer|May 15, 1987
Circulating IgA immune complexes in head and neck cancer, nasopharyngeal carcinoma, lung cancer, and colon cancerM W Baseler, P E Maxim, R W Veltri
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1993
Immunological monitoring and clinical trials of biological response modifiersM W Baseler, W C Kopp, W J Urba
The Journal of Experimental Medicine|April 1, 1990
Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodiesC F Perno, M W Baseler, S Broder, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)|October 1, 1981
Acute-phase reactants in experimental inhalation lung diseaseM W Baseler, R Burrell
Inflammation|December 1, 1983
Purification of haptoglobin and its effects on lymphocyte and alveolar macrophage responsesM W Baseler, R Burrell
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1992
Immunological monitoring and clinical trials of biological response modifiersM W Baseler, W J Urba
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1990
Immunological monitoring and clinical trials of biological response modifiersW J Urba, M W Baseler
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1991
Immunological monitoring and clinical trials of biological response modifiersM W Baseler, W J Urba
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1988
Immunological monitoring and clinical trials of biological response modifiersW J Urba, M W Baseler
Infection and Immunity|April 1, 1983
Differential toxicity of inhaled gram-negative bacteriaM W Baseler, B Fogelmark, R Burrell
Cancer|May 15, 1987
Circulating IgA immune complexes in head and neck cancer, nasopharyngeal carcinoma, lung cancer, and colon cancerM W Baseler, P E Maxim, R W Veltri
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1993
Immunological monitoring and clinical trials of biological response modifiersM W Baseler, W C Kopp, W J Urba
The Journal of Experimental Medicine|April 1, 1990
Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodiesC F Perno, M W Baseler, S Broder, et al.
Pageof 3